Analysis Hua Medicine (HUMDF)
5/30/2024
Analysis of Hua Medicine (HUMDF)
Hua Medicine (HUMDF) has been trading at a consistent price of 0.20280 over the past several days, as indicated by the closing, opening, low, and high prices. The technical indicators such as RSI, MACD, and moving averages (SMA, EMA, WMA) are also showing no significant changes or signals.Based on this data, it appears that Hua Medicine stock is currently stable with no major price movements or significant changes in the technical indicators. Further analysis or additional data would be needed to provide a more comprehensive assessment of the stock's performance and potential future trends.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous results, ending on February 27, 2025, were handled by the Transfer Agent. The results for January 31, 2025, were released after hours. The results for October 31, 2024, were not supplied at the time. The results for August 1, 2024, showed an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive current ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and it has shown a positive return on assets and return on equity.
Looking at stock statistics, the company has a low short ratio and a significant percentage of shares held by institutions. The stock price has fluctuated between a fifty-two-week low and high, with a positive change over the period.
Valuation metrics show a relatively high PEG ratio and price-to-book ratio. The company's market capitalization and enterprise value are substantial, with moderate price-to-sales and enterprise-to-EBITDA ratios.
The stock price summary includes beta, moving averages, and the range of prices over the past year.
Lastly, dividends and splits information shows the company's dividend history, payout ratio, and dividend yield metrics. The company has a regular dividend payout and has undergone a stock split in the past.
Income statement 💸
Here are the revenue figures for the company over the past four fiscal years:- 2020: $274,515,000,000
- 2021: $365,817,000,000
- 2022: $394,328,000,000
- 2023: $383,285,000,000
From these numbers, we can observe that the company has experienced steady revenue growth from 2020 to 2022, with a slight decrease in revenue in 2023 compared to the previous year. This trend indicates a generally positive trajectory in terms of sales performance over the past few years.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets fluctuate, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2018 at $234,386,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has shown an increasing trend, with the highest value in 2018 at $107,147,000,000.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company seems to be managing its cash flow effectively, with a focus on operational efficiency and strategic investments.
Earnings estimate
The analysts' estimates for future quarterly and annual earnings per share are as follows:1. Current Quarter (as of June 30, 2024):
- Average Estimate: $1.33
- Low Estimate: $1.27
- High Estimate: $1.36
- Number of Analysts: 26
- Year Ago EPS: $1.26
2. Next Quarter (as of September 30, 2024):
- Average Estimate: $1.53
- Low Estimate: $1.44
- High Estimate: $1.63
- Number of Analysts: 25
- Year Ago EPS: $1.46
3. Current Year (as of September 30, 2024):
- Average Estimate: $6.59
- Low Estimate: $6.43
- High Estimate: $6.92
- Number of Analysts: 39
- Year Ago EPS: $6.13
4. Next Year (as of September 30, 2025):
- Average Estimate: $7.23
- Low Estimate: $6.40
- High Estimate: $7.90
- Number of Analysts: 39
- Year Ago EPS: $6.59
Based on these estimates, we can see a generally positive outlook with an increase in earnings per share expected for both the next quarter and the next year compared to the previous periods. The number of analysts providing estimates also indicates a strong interest in the company's performance.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth rates expected in the next fiscal year.
Growth estimates
Based on the consensus estimates provided:- The company is expected to experience a growth rate of 7.5% in the current year and 9.7% in the next year.
- For the current quarter, the growth rate is estimated to be 5.6%, while for the next quarter it is projected to be 4.8%.
- Over the next 5 years, the company is expected to have a compound annual growth rate (CAGR) of 11%.
- However, when looking at the past 5 years, the company has achieved a higher CAGR of approximately 20.1%.
Overall, the company is expected to maintain a positive growth trajectory, with a slightly lower growth rate in the short term compared to the long-term projections.
Price target
Based on the analysts' forecast, the future price of the security is expected to range between $164 (low) and $250 (high), with a median estimate of $200 and an average estimate of $202.26. The current price of the security is $191.57.MACD of HUMDF
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
